Kalaris news
Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Leone Patterson to its Board of Directors and as Chair of the Board’s Audit Committee.
“We’re delighted to welcome Leone as Chair of the Board’s Audit Committee,” said David Hallal, Chairman of the
- Phase 2 study completed enrollment ahead of schedule
- Posoleucel well-tolerated with no cases of graft rejection observed to date
- Overall decline in median BK viral load among patients completing 12 weeks of dosing with posoleucel or placebo (2:1 randomization)
- Posoleucel detected up to 12 weeks after last infusion
- Topline, unblinded study results from all 61 patients expected to be released in 1Q 2023<
- Initiated posoleucel registrational study to prevent six devastating viral infections and now enrolling high-risk allo-HCT patients in the U.S., Western Europe and Asia
- FDA granted RMAT designation to posoleucel for Phase 3 multi-virus prevention indication with an estimated annual addressable patient population of 40,000 allo-HCT patients
- Progressed enrollment in three Phase 3 studies for posoleucel and a Phase 2 trial for
AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead investigational multi-virus-specific T cell therapy, posoleucel, for the prevention of clinically significant infections and disease from six devastating viruses that commonly impact high-risk adult and pediat
AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello brings more than 35 years of broad experience building and leading commercial organizations in the life sciences industry, with specific expertise in cell and gene therapy.
“We’re thrilled to welcome Shawn to
- Updated, preliminary Phase 2 data presented at EBMT Annual Meeting continue to demonstrate substantial reduction in the expected rate of clinically significant infections with posoleucel therapy
- 21 of 24 patients were free of clinically significant infections through the Week 14 primary endpoint
AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the initiation of a
AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:00 a.m. EST.
A live webcast of the fireside chat will be available on the Investors & Press sectio
- Three ongoing Phase 3 registrational studies of posoleucel expected in 2022, targeting treatment and prevention indications with no approved therapies
- Expanded enrollment in Phase 2 proof-of-concept study of posoleucel for the preemptive treatment of BK viremia in kidney transplant recipients; initial data submitted for presentation in 1H 2022
- Advancing two additional virus-specific T cell therapies – ALVR106 to treat common respiratory v
- Treatment of AdV infection is posoleucel’s second potential indication to receive RMAT designation
- Phase 3 registrational study of posoleucel for AdV treatment is now open for enrollment
- Proof-of-concept study of ALVR106 for the treatment of multiple respiratory viral infections is also open for enrollment
AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, today announced that the
AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 4:30 p.m. ET.
An audio-only webcast of the presentation will be available on the Investors & Press section of the